Your browser doesn't support javascript.
loading
The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
Qiu, Qiao-Cheng; Wang, Chao; Bao, Xie-Bing; Yang, Jing; Shen, Hong-Jie; Ding, Zi-Xuan; Liu, Hong; He, Jun; Yao, Hong; Chen, Su-Ning; Li, Zheng; Xue, Sheng-Li; Liu, Song-Bai.
Afiliación
  • Qiu QC; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Wang C; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Bao XB; b Department of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Yang J; c Department of Clinical Nutrition , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Shen HJ; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Ding ZX; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Liu H; d Biobank of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • He J; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Yao H; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Chen SN; e Collaborative Innovation Center of Hematology , Soochow University , Suzhou , China.
  • Li Z; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Xue SL; b Department of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
  • Liu SB; a Jiangsu Institute of Hematology , The First Affiliated Hospital of Soochow University , Suzhou , China.
Hematology ; 23(3): 131-138, 2018 Apr.
Article en En | MEDLINE | ID: mdl-28876197
ABSTRACT

OBJECTIVE:

Two distinct forms of FMS-like tyrosine kinase 3 (FLT3) mutations, internal tandem duplication (ITD) in the juxtamembrane domain and point mutation within the activation loop of the tyrosine kinase domain (TKD), have been identified in considerable number of patients with AML. This study was aimed to analyze the impacts of these mutations on clinical outcomes, and assess the efficacy of different therapeutic regimens (allo-HSCT, sorafenib, or conventional chemotherapy) for AML patients with FLT3 mutations after the standard induction therapy. MATERIALS AND

METHODS:

We analyzed DNA samples from 158 consecutive de novo AML patients (18-60 years, excluding APL) with FLT3 mutations between July 2010 and October 2015.

RESULTS:

We found that AML patients with FLT3-TKD mutations have more favorable clinical outcomes than those with FLT3-ITD mutations. We also found that allo-HSCT therapy subgroup achieved longer OS and RFS than non-allo-HSCT therapy subgroup for FLT3-ITD positive patients (p < 0.001, p = 0.071). However, compared with the clinical outcomes in non-primary refractory patients, sorafenib did not show an obvious beneficial effect for the primary refractory patients. Further study on a large scale is still recommended.

CONCLUSIONS:

FLT3-TKD-mutated AML patients have more favorable clinical outcomes than those with FLT3-ITD mutations. Allo-HSCT therapy subgroup achieved longer OS and RFS than non-allo-HSCT therapy subgroup for FLT3-ITD positive patients. Compared with the clinical outcomes in non-primary refractory patients, sorafenib did not show an obvious beneficial effect for the primary refractory patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide / Tirosina Quinasa 3 Similar a fms / Mutación Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide / Tirosina Quinasa 3 Similar a fms / Mutación Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: China